 - Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for MDS or MPD e.g., thalidomide or lenalidomide, interferon, cytokines, low-dose 5-azacytidine, low-dose cytoxan will be eligible for this trial 